Status:
COMPLETED
A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
Advanced Pancreatic Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to determine whether an investigational immuno-therapy, cabiralizumab in combination with nivolumab, with or without chemotherapy, is effective for the treatment of advanc...
Eligibility Criteria
Inclusion
- Must have histological or cytological confirmed diagnosis of locally advanced or metastatic adenocarcinoma of the pancreas, which has progressed on or after one line of chemotherapy
- ECOG Performance status 0-1
- Adequate organ functions
- Measurable disease
Exclusion
- Suspected or known CNS metastasis
- Participants with active, known, or suspected autoimmune disease
- Uncontrolled or significant cardiovascular disease
- Prior exposure to selected immune cell-modulating antibody regimens
Key Trial Info
Start Date :
December 18 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2023
Estimated Enrollment :
205 Patients enrolled
Trial Details
Trial ID
NCT03336216
Start Date
December 18 2017
End Date
June 1 2023
Last Update
July 23 2024
Active Locations (41)
Enter a location and click search to find clinical trials sorted by distance.
1
Mayo Clinic in Rochester, Minnesota
Phoenix, Arizona, United States, 85054
2
HonorHealth Research Institute
Scottsdale, Arizona, United States, 85258
3
Local Institution - 0007
Los Angeles, California, United States, 90095
4
University Of Colorado
Aurora, Colorado, United States, 80045